Skip to main content

Main menu

  • Home
  • Current issue
  • ERJ Early View
  • Past issues
  • For authors
    • Instructions for authors
    • Submit a manuscript
    • Author FAQs
    • Open access
    • COVID-19 submission information
  • Alerts
  • Podcasts
  • Subscriptions
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

User menu

  • Log in
  • Subscribe
  • Contact Us
  • My Cart

Search

  • Advanced search
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

Login

European Respiratory Society

Advanced Search

  • Home
  • Current issue
  • ERJ Early View
  • Past issues
  • For authors
    • Instructions for authors
    • Submit a manuscript
    • Author FAQs
    • Open access
    • COVID-19 submission information
  • Alerts
  • Podcasts
  • Subscriptions

Self-titration of inhaled corticosteroid and beta2-agonist in response to symptoms in mild asthma – a pre-specified analysis from the PRACTICAL study, a randomised controlled trial

Christina Baggott, Jo Hardy, Jenny Sparks, Mark Holliday, Daniela Hall, Alexandra Vohlidkova, Robert Hancox, Mark Weatherall, James Fingleton, Richard Beasley on behalf of the PRACTICAL study team
European Respiratory Journal 2020; DOI: 10.1183/13993003.00170-2020
Christina Baggott
1Medical Research Institute of New Zealand, Wellington, New Zealand
2Victoria University of Wellington, Wellington, New Zealand
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Christina Baggott
  • For correspondence: christina.baggott@mrinz.ac.nz
Jo Hardy
1Medical Research Institute of New Zealand, Wellington, New Zealand
2Victoria University of Wellington, Wellington, New Zealand
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jenny Sparks
1Medical Research Institute of New Zealand, Wellington, New Zealand
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Mark Holliday
1Medical Research Institute of New Zealand, Wellington, New Zealand
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Daniela Hall
1Medical Research Institute of New Zealand, Wellington, New Zealand
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Alexandra Vohlidkova
1Medical Research Institute of New Zealand, Wellington, New Zealand
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Robert Hancox
3University of Otago, Dunedin, New Zealand
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Robert Hancox
Mark Weatherall
4University of Otago, Wellington, New Zealand
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
James Fingleton
1Medical Research Institute of New Zealand, Wellington, New Zealand
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for James Fingleton
Richard Beasley
1Medical Research Institute of New Zealand, Wellington, New Zealand
2Victoria University of Wellington, Wellington, New Zealand
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Richard Beasley
  • Article
  • Info & Metrics
  • PDF
Loading

Abstract

Background In mild asthma, as-needed budesonide-formoterol is superior or non-inferior to maintenance budesonide plus as-needed short-acting beta2-agonist in reducing severe exacerbations. In this pre-specified analysis, we investigated patterns of inhaled corticosteroid (ICS) and beta2-agonist use in PRACTICAL, a randomised controlled trial.

Methods Participants were randomised 1:1 to as-needed budesonide-formoterol (200/6 mcg Turbuhaler, 1 prn) or maintenance budesonide (200 mcg Turbuhaler, 1 bd) with as-needed terbutaline (250 mcg, 2 prn) for 52 weeks; 110 participants had electronic monitors attached to their study inhalers which captured the time and date of every actuation. Key outcome measures were patterns of ICS and beta2-agonist use. One actuation of budesonide-formoterol was considered to be an equivalent bronchodilator dose as two actuations of terbutaline.

Findings Participants randomised to as-needed budesonide-formoterol had more days with no ICS use compared with maintenance budesonide (median total days of no use 156 versus 22 days respectively), lower median daily budesonide dose (164 versus 328 mcg respectively), and a greater median number of days of ≥4 budesonide actuations (4 versus 1 days respectively). Participants randomised to as-needed budesonide-formoterol took higher equivalent doses of beta2-agonist both overall (median number of actuations 0.8 versus 0.3 per day respectively) and in response to worsening asthma (total number of “overuse days” of >8 or >16 actuations of budesonide-formoterol or terbutaline 33 versus 10 respectively).

Interpretation The timing of ICS dose when self-titrated to beta2-agonist use is more important than total ICS dose in reducing severe exacerbation risk in mild asthma, when associated with greater overall use of as-needed beta2-agonist.

Footnotes

This manuscript has recently been accepted for publication in the European Respiratory Journal. It is published here in its accepted form prior to copyediting and typesetting by our production team. After these production processes are complete and the authors have approved the resulting proofs, the article will move to the latest issue of the ERJ online. Please open or download the PDF to view this article.

Conflict of interest: Dr. Baggott reports grants from Health Research Council of New Zealand, during the conduct of the study; non-financial support from Astra Zeneca, non-financial support from Novartis, outside the submitted work.

Conflict of interest: Dr. Hardy reports grants from Health Research Council of New Zealand, during the conduct of the study; other from Astra Zeneca, outside the submitted work.

Conflict of interest: Ms. Sparks reports grants from Health Research Council of New Zealand, during the conduct of the study.

Conflict of interest: Mr. Holliday reports grants from Health Research Council of New Zealand, during the conduct of the study.

Conflict of interest: Dr. Hall reports grants from Health Research Council of New Zealand, during the conduct of the study.

Conflict of interest: Dr. Vohlidkova reports grants from Health Research Council of New Zealand, during the conduct of the study.

Conflict of interest: Dr. Hancox reports grants from Health Research Council of New Zealand, during the conduct of the study; other from Astra Zeneca, other from Menarini, other from Boehringer Ingelheim, outside the submitted work.

Conflict of interest: Prof. Weatherall reports grants from Health Research Council of New Zealand, during the conduct of the study.

Conflict of interest: Dr. Fingleton reports grants from Health Research Council of New Zealand, during the conduct of the study; grants, personal fees and non-financial support from AstraZeneca, grants and personal fees from GlaxoSmithKline, grants from Genentech, personal fees and non-financial support from Boerhinger Ingleheim, outside the submitted work.

Conflict of interest: Dr. Beasley reports grants from Health Research Council of New Zealand, during the conduct of the study; grants and personal fees from AstraZeneca, grants and personal fees from GlaxoSmithKline, grants from Genentech, personal fees from Avillion, personal fees from Theravance, outside the submitted work.

  • Received January 26, 2020.
  • Accepted May 17, 2020.
  • Copyright ©ERS 2020
View Full Text

ERS Members

myERS - ERS members : log in with your myERS username and password.

INDIVIDUALS

Log in Login as an individual user.

Forgot your username or password?

LIBRARY USERS

Log in through your institution

If your library has a subscription, you may already be logged in via your IP address. Otherwise you may be able to log in via one of the following routes.
You may be able to gain access using your login credentials for your institution. Contact your library if you do not have a username and password.
If your organization uses OpenAthens, you can log in using your OpenAthens username and password. To check if your institution is supported, please see this list. Contact your library for more details.
If you think you should have access, please contact your librarian or email journals@ersnet.org

Purchase access

You may purchase access to this article. This will require you to create an account if you don't already have one.
PreviousNext
Back to top
View this article with LENS
Vol 57 Issue 4 Table of Contents
European Respiratory Journal: 57 (4)
  • Table of Contents
  • Index by author
Email

Thank you for your interest in spreading the word on European Respiratory Society .

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Self-titration of inhaled corticosteroid and beta2-agonist in response to symptoms in mild asthma – a pre-specified analysis from the PRACTICAL study, a randomised controlled trial
(Your Name) has sent you a message from European Respiratory Society
(Your Name) thought you would like to see the European Respiratory Society web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Print
Alerts
Sign In to Email Alerts with your Email Address
Citation Tools
Self-titration of inhaled corticosteroid and beta2-agonist in response to symptoms in mild asthma – a pre-specified analysis from the PRACTICAL study, a randomised controlled trial
Christina Baggott, Jo Hardy, Jenny Sparks, Mark Holliday, Daniela Hall, Alexandra Vohlidkova, Robert Hancox, Mark Weatherall, James Fingleton, Richard Beasley
European Respiratory Journal Jan 2020, 2000170; DOI: 10.1183/13993003.00170-2020

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Self-titration of inhaled corticosteroid and beta2-agonist in response to symptoms in mild asthma – a pre-specified analysis from the PRACTICAL study, a randomised controlled trial
Christina Baggott, Jo Hardy, Jenny Sparks, Mark Holliday, Daniela Hall, Alexandra Vohlidkova, Robert Hancox, Mark Weatherall, James Fingleton, Richard Beasley
European Respiratory Journal Jan 2020, 2000170; DOI: 10.1183/13993003.00170-2020
del.icio.us logo Digg logo Reddit logo Technorati logo Twitter logo CiteULike logo Connotea logo Facebook logo Google logo Mendeley logo
Full Text (PDF)

Jump To

  • Article
    • Abstract
  • Info & Metrics
  • PDF

Subjects

  • Asthma and allergy
  • Tweet Widget
  • Facebook Like
  • Google Plus One

More in this TOC Section

  • Breathlessness in COPD: linking symptom clusters with brain activity
  • Outcomes of patients with decreased arterial oxyhaemoglobin saturation on pulmonary arterial hypertension drugs
  • Dyspnea and respiratory muscles ultrasound to predict extubation failure
Show more Original article

Related Articles

Navigate

  • Home
  • Current issue
  • Archive

About the ERJ

  • Journal information
  • Editorial board
  • Reviewers
  • CME
  • Press
  • Permissions and reprints
  • Advertising

The European Respiratory Society

  • Society home
  • myERS
  • Privacy policy
  • Accessibility

ERS publications

  • European Respiratory Journal
  • ERJ Open Research
  • European Respiratory Review
  • Breathe
  • ERS books online
  • ERS Bookshop

Help

  • Feedback

For authors

  • Instructions for authors
  • Submit a manuscript
  • ERS author centre

For readers

  • Alerts
  • Subjects
  • Podcasts
  • RSS

Subscriptions

  • Accessing the ERS publications

Contact us

European Respiratory Society
442 Glossop Road
Sheffield S10 2PX
United Kingdom
Tel: +44 114 2672860
Email: journals@ersnet.org

ISSN

Print ISSN:  0903-1936
Online ISSN: 1399-3003

Copyright © 2021 by the European Respiratory Society